Passa al contenuto
Merck

The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.

American journal of physiology. Heart and circulatory physiology (2013-09-03)
Tuomas T Rissanen, Jussi Nurro, Paavo J Halonen, Miikka Tarkia, Antti Saraste, Markus Rannankari, Krista Honkonen, Mikko Pietilä, Olli Leppänen, Antti Kuivanen, Juhani Knuuti, Seppo Ylä-Herttuala
ABSTRACT

A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches. In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape. The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk. Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed. Pigs were given antiarrhythmic medication to prevent sudden death. The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication. Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model. Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion. Dynamic and competitive collateral growth patterns were observed. EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively. The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model. The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Polytetrafluoroethylene preparation, 60 wt % dispersion in H2O
Sigma-Aldrich
Poly(tetrafluoroethylene), powder (free-flowing), 1 μm particle size
Sigma-Aldrich
Poly(tetrafluoroethylene), powder, >40 μm particle size
Sigma-Aldrich
Poly(tetrafluoroethylene), powder, 200 μm particle size
Sigma-Aldrich
Poly(tetrafluoroethylene), beads
Sigma-Aldrich
Poly(tetrafluoroethylene), powder, 35 μm particle size
Sigma-Aldrich
Poly(tetrafluoroethylene), powder (free-flowing), ≤12 μm particle size
Sigma-Aldrich
Poly(tetrafluoroethylene), powder, ≥350 μm particle size